Dublin, Nov. 09, 2018 (GLOBE NEWSWIRE) -- The "Blood Plasma: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.
Sales of Blood Therapeutics were $30.9 Billion in 2017 and by 2024, These Products will Reach $57.5 Billion, Reflecting a Five-Year CAGR of 8.2%.
Worldwide markets are poised to achieve continuing growth as animal and human blood is further fractionated to address more disease treatments and becomes more effective in the research and development aspects of medical care delivery.
Blood is for most species the essence of life. Blood plasma provides significant health benefits. The varieties of proteins and other components of blood are in demand worldwide. Blood proves its value by managing a variety of ways to treat disease.
The plasma proteins or derivatives in blood are extracted via the fractionation process. A range of valuable products are manufactured from blood plasma through fractionation. Fractionation occurs in tanks at near freezing temperatures. Fractionation is used to maintain the integrity of the proteins in plasma. This process includes a phase of introducing various viral inactivation procedures.
Blood plasma offers high value for its volume and weight. One refrigerated container might be worth more than an entire shipload of grain. Blood provides significant health benefits to people. Blood exports boost U.S. exports with minimal carbon emissions.
Liver disease is a major cause of illness and death worldwide. In China, 400 million people have liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]). Nonalcoholic fatty liver disease and alcoholic liver diseases are also prevalent diagnoses.
The blood plasma market is driven in part by China, and by demand from China for high-quality blood from the US. Chinese patients consumed 400 metric tons of serum albumin in 2017, half of the global total of that blood protein. The necessary supply could be provided by the Chinese population, but, many of them are afraid to donate blood.
As a result, China has to import about 60% of its serum albumin-and the ever-rising demand has driven up prices. American companies have an edge in the Chinese markets because of the quality of the blood collected. The edge is apparent in the fact that three foreign companies account for 88% of China's serum albumin imports.
The billion-dollar market for blood worldwide has a variety of participants. Thermo Fisher Scientific has the largest market participation. Sales of blood therapeutics were $30.9 billion in 2017. By 2024, these products reach $57.5 billion, reflecting a five-year CAGR of 8.2%.
Key Topics Covered:
1. Blood: Market Description And Market Dynamics
1.1 Blood Plasma
1.2 Liver Disease Is A Major Cause Of Illness And Death In China
1.3 Plasma Products Market Trends
2. Blood Market Shares And Forecasts
2.1 Blood Market Driving Forces
2.2 Serum (Blood) Market Shares
2.3 Serum (Blood) Market Forecasts
2.4 Serum (Blood) Market Segment Forecasts
2.5 Animal and Bovine Serum Market Segments, FBS, ABS, NBCS, BS, Porcine Sera, Dollars, Worldwide, 2017
2.6 Serum (Blood) Prices
2.7 Serum (Blood) Regional Market
3. Serum (Blood) Product Description
3.1 Plasma Source of Life
3.2 Plasma Vital To The Regulation Of Body Functions
3.3 Immunoglobulin Products
3.4 Albumin products
3.5 Clotting Factor and Other Products
4. Blood Research And Technology
4.1 Bovine Serum
4.2 Genetically Engineered Blood Products
4.3 Government Regulation
4.4 Cord Blood
4.5 Chinese Serum Contaminated with AIDS Virus
4.6 Chinese Biological Product Regulations
4.7 Chinese Drug Industry Under Attack
5 Serum (Blood) Company Profiles
5.1 ANZCO Foods / Bovogen Biologicals
5.2 Ausgenex Pty Ltd
5.3 Avantor
5.4 Biochrom GmbH
5.5 Biotest AG
5.6 BPL Group
5.7 Cellsera Rutherford
5.8 Changchun SRbiological
5.9 China Biologic Products
5.10 Chinese Plasma Market and Acquisitions
5.11 Corning Life Sciences
5.12 Global Cord Blood Corp.
5.13 CSL
5.14 ExCel Bio
5.15 GE Healthcare Life Sciences
5.16 Grifols S.A. (GRFS)
5.17 Hualan Biological Engineering Inc.
5.18 Kedrion S.p.A.
5.19 Lake Immunogenics
5.20 Lanzhou Minhai
5.21 LFB Biotechnologies
5.22 Mallinckrodt
5.23 Merck KGaA / Millipore / Sigma-Aldrich
5.24 Moregate Biotech
5.25 Newman Biotech
5.26 Octopharma AG
5.27 Sanpower Group
5.28 Selborne Biological Services
5.29 Proliant
5.30 Shanghai RAAS
5.31 Rocky Mountain Biologicals (RMBIO)
5.32 Sanquin
5.33 Takeda / Shire
5.34 South Pacific Sera
5.35 Thermo Fisher Scientific
5.36 Beijing Tiantan Biological Products
5.37 Wuhan Sanli
5.38 Wolongsong
5.39 ZenBio
5.40 Selected Chinese Blood Companies
For more information about this report visit https://www.researchandmarkets.com/research/pfhng6/sales_of_blood?w=12
Source: Wintergreen Research, Inc
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.